Therapeutic Solutions International Spin Off Campbell Neurosciences Announces Novel Mechanistic Data on CampbellCell Stem Cell Therapy for Schizophrenia

Rhea-AI Summary

Therapeutic Solutions International (TSOI) announced new findings from its spin-off, Campbell Neurosciences, revealing that CampbellCell universal donor stem cells help alleviate schizophrenia symptoms in animal models by enhancing immune modulation and boosting brain-derived neurotrophic factors (BDNF). The research indicated increased interleukin-4 production, which helps counter inflammatory cytokines like interleukin-17. Dr. Thomas Ichim highlighted the ongoing development of a biomarker for suicidal ideations, while Timothy Dixon praised the innovative approach combining immunotherapy and regenerative medicine for mental health treatment.

Positive

• CampbellCell stem cells show promise in reducing schizophrenia symptoms through immune modulation.
• Progress in developing a saliva-based biomarker for suicidal ideation detection.
• Combination of immunotherapy and regenerative medicine may lead to innovative mental health treatments.

Negative

• None.

Company Advances towards First Cell Therapy to Prevent Suicidal Associated Mental Illness

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced new data, covered by its previously filed patents, demonstrating that CampbellCell universal donor stem cells reduce symptoms of schizophrenia in an animal model through stimulation of immune modulation and production of the cytokine brain derived neurotrophic factors (BDNF).

In a series of experiments, it was demonstrated that CampbellCell administration resulted in upregulated production of the cytokine interleukin-4, which was needed to reduce the inflammatory cytokine interleukin-17 and to suppress schizophrenia development.

“Campbell Neurosciences is making substantial progress in development of a biomarker-based test for suicidal ideations which involves saliva based detection of inflammatory cytokines,” said Dr. Thomas Ichim, President, and CEO of Campbell Neurosciences. “In parallel we are developing the CampbellCell, which is a mesenchymal lineage stem cell that is optimized for production of neurotrophic factors, which are believed to help in patients suffering from brain inflammation, particularly the type of brain inflammation associated with schizophrenia.”

Schizophrenia is a significant cause of suicide and has been associated with multiple immunological abnormalities. Experiments such as the ones reported today suggest that suppression of brain inflammation may have a positive effect on schizophrenia treatment. The utilization of our CampbellCell for treatment of schizophrenia was also associated with modulation of several immune cells including M2 monocytes and natural killer T cells.

“We are extremely pleased with the rapid pace of progress at Campbell Neurosciences, which to my knowledge is the only company leveraging immunotherapy and regenerative medicine to address diagnosis and treatment of mental diseases,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International. “I commend Dr. Ichim for his enormous contributions, including being inventor on over 300 issued and published patent applications. I am happy to see that the goal of Campbell Neurosciences, which is a world without suicide, is getting closer and closer to being accomplished.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

About Campbell Neurosciences, Inc.

Campbell Neurosciences is committed to establishing a biological basis for diagnosis and treatment of suicide and its causes, including Schizophrenia and other mental health disorders, thereby eliminating the stigma of the disease. The Company's corporate website is www.campbellneurosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230403005510/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International, Inc.

FAQ

What did Therapeutic Solutions International (TSOI) announce regarding Campbell Neurosciences?

TSOI announced new data showing that CampbellCell universal donor stem cells reduce symptoms of schizophrenia in animal models.

When were the findings about CampbellCell stem cells released?

The findings were announced in a press release dated April 3, 2024.

How do CampbellCell stem cells impact schizophrenia treatment?

They enhance immune modulation and increase production of brain-derived neurotrophic factors, potentially alleviating symptoms.

What is the goal of Campbell Neurosciences based on the press release?

The goal is to establish a biological basis for diagnosing and treating suicide and related mental health disorders.

What cytokines are involved in the research reported by TSOI?

The research highlights interleukin-4 and interleukin-17 in the context of immune modulation for schizophrenia.